z-logo
open-access-imgOpen Access
Programmed Cell Death 1-Directed Immunotherapy for Enhancing T-Cell Function
Author(s) -
Koichi Araki,
Ben Youngblood,
Rafi Ahmed
Publication year - 2013
Publication title -
cold spring harbor symposia on quantitative biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.615
H-Index - 77
eISSN - 1943-4456
pISSN - 0091-7451
DOI - 10.1101/sqb.2013.78.019869
Subject(s) - immunotherapy , blockade , effector , cancer immunotherapy , t cell , regulator , cancer , medicine , epigenetics , immunology , cancer research , cell , pd l1 , immune system , biology , receptor , biochemistry , genetics , gene
T-cell exhaustion is a unique state that appears during many chronic infections and cancer and is characterized by loss of proliferative capacity and effector function. Complex mechanisms are involved in this T-cell dysfunction but an inhibitory receptor, PD-1, has been identified as a major regulator of T-cell exhaustion. Blockade of the PD-1 pathway can reinvigorate exhausted T cells, resulting in better control of chronic infections and cancer. Notably, recent clinical studies have revealed that PD-1-directed immunotherapy is highly effective in cancer patients, demonstrating that PD-1 is a promising therapeutic target in humans. In this review, we summarize our current understanding of the epigenetic regulation of PD-1 expression in T cells and discuss potential combination therapy with PD-1 blockade toward developing more effective treatment for chronic infections and cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom